LONG-TERM DURABLE RESPONSES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (RJR) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), AND FOLLICULAR LYMPHOMA (FL) TREATED WITH TISAGENLECLEUCEL (TISA-CEL) AND ITS ASSOCIATION WITH PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

被引：0

作者：

Awasthi, R. ^{[1
]}

Waldron, E. ^{[2
]}

Grupp, S. A. ^{[3
,4
]}

Pulsipher, M. A. ^{[5
]}

Bader, P. ^{[6
]}

Schuster, S. J. ^{[7
]}

Maziarz, R. ^{[8
]}

Waller, E. ^{[9
]}

Jager, U. ^{[10
]}

Thieblemont, C. ^{[11
]}

Dreyling, M. ^{[12
]}

Fowler, N. ^{[13
,14
]}

Maier, H. J. ^{[15
]}

Willert, J. ^{[2
]}

机构：

[1] Novartis Inst BioMed Res, E Hanover, NJ USA

[2] Novartis Pharmaceut, E Hanover, NJ USA

[3] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA

[4] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA

[5] Univ Utah, Spencer Fox Eccles Sch Med, Intermt Primary Childrens Hosp, Div Hematol & Oncol,Huntsman Canc Inst, Salt Lake City, UT USA

[6] Goethe Univ Frankfurt, Univ Hosp, Div Stem Cell Transplantat Immunol & Intens Care, Dept Pediat, Frankfurt, Germany

[7] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA

[8] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[9] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA

[10] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med, Vienna, Austria

[11] Hop St Louis, AP HP, Paris, France

[12] LMU Munchen, Klinikum Univ, Med Klin 3, Munich, Germany

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[14] BostonGene, Waltham, MA USA

[15] Novartis Pharma AG, Basel, Switzerland

来源：

关键词：

CAR-T cell therapy; Lymphoid Malignancies; Tisagenlecleucel;

D O I：

暂无

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

906

引用

页码：S152 / S152

页数：1